NCT03492788 (optCRT) is a NA clinical trial of ECGI-optimized VV-offset in Heart Failure, Systolic, sponsored by Washington University School of Medicine.

Who is sponsoring NCT03492788?

NCT03492788 is sponsored by Washington University School of Medicine.

What drugs are being tested in NCT03492788?

Interventions in NCT03492788: ECGI-optimized VV-offset, Zero VV-offset.

What condition does NCT03492788 study?

NCT03492788 studies Heart Failure, Systolic, Left Bundle-Branch Block.

Is NCT03492788 still recruiting?

NCT03492788 is currently terminated. Last updated 1 May 2019.

Last reviewed 2019-05-01 · How we verify

NCT03492788: optCRT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Optimizing CRT With ECGI

Terminated NA Last updated 1 May 2019

What this trial tests

NA trial testing ECGI-optimized VV-offset in Heart Failure, Systolic in 3 participants. Terminated before completion.

Timeline

28 December 2017

Primary endpoint
5 October 2018

5 October 2018

Quick facts

Lead sponsor	Washington University School of Medicine
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	3
Start date	28 December 2017
Primary completion	5 October 2018
Estimated completion	5 October 2018
Sites	1 location across United States

Drugs / interventions tested

ECGI-optimized VV-offset
Zero VV-offset

Conditions studied

Heart Failure, Systolic — all drugs for Heart Failure, Systolic →
Left Bundle-Branch Block — all drugs for Left Bundle-Branch Block →

Sponsor

Washington University School of Medicine

Who can join

Adults 18 to 100, any sex, with Heart Failure, Systolic or Left Bundle-Branch Block. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

CRT is delivered from two electrodes on opposite sides of the heart \[right (RV) and left ventricle (LV)\] delivering stimulation for more efficient heart beats. There is flexibility in the sequence and temporal staggering of the stimulation from these two electrodes with a different optimum for different patients. However, standard techniques to figure out the optimal stimulation strategy like standard 12-lead surface electrical recording (ECG) or routine ultrasound have failed. The investigators have developed ECG imaging (ECGI) with 250 electrode surface recording combined with CT scan to reconstruct high resolution 4-dimensional panoramic electrical maps of the heart. The study seeks to enroll 56 patients undergoing CRT in a clinical trail to evaluate short and long term impact of using ECGI for optimal programming of CRT.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Heart Failure, Systolic

Currently open trials in the same condition.

NCT07199088 — Comparative Efficacy and Safety of Acetazolamide Versus Metolazone as an Adjunct to Standard Therapy in Patients With Ac · NA · recruiting
NCT06336746 — Cardiac Performance During Steep Trendelenburg Position in Patients Undergoing Robotic Surgery Surgery. · recruiting
NCT06675552 — Non-interventional Study on Guideline Directed Medical Therapy for Patients With Heart Failure (HF) in Germany · recruiting
NCT06332391 — Paced Heart Rate Acceleration for Cardiac Conditioning · NA · recruiting
NCT05632432 — Atrial Appendage Micrograft Transplants to Assist Heart Repair After Cardiac Surgery · NA · recruiting

Other Washington University School of Medicine trials

Trials by the same sponsor.

NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) · Phase 1 · not yet recruiting
NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients · not yet recruiting
NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03492788 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
Last refreshed: 1 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03492788.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing